Waters upgraded by Jefferies with a new price target
$WAT
Biotechnology: Laboratory Analytical Instruments
Industrials
Jefferies upgraded Waters from Hold to Buy and set a new price target of $415.00 from $355.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/31/2025 | $460.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 3/26/2025 | $396.00 → $407.00 | Neutral → Outperform | Robert W. Baird |
| 2/13/2025 | $450.00 | Sector Perform → Sector Outperform | Scotiabank |
| 2/10/2025 | $360.00 → $415.00 | Underweight → Equal Weight | Barclays |
| 1/10/2025 | $430.00 | Mkt Perform → Outperform | Bernstein |
| 12/23/2024 | Sector Perform | Scotiabank | |
| 10/8/2024 | $355.00 → $415.00 | Hold → Buy | Jefferies |
| 8/28/2024 | $380.00 | Overweight | Wells Fargo |
4 - WATERS CORP /DE/ (0001000697) (Issuer)
425 - WATERS CORP /DE/ (0001000697) (Subject)
425 - WATERS CORP /DE/ (0001000697) (Subject)
10-Q - WATERS CORP /DE/ (0001000697) (Filer)
KeyBanc Capital Markets upgraded Waters from Sector Weight to Overweight and set a new price target of $460.00
Robert W. Baird upgraded Waters from Neutral to Outperform and set a new price target of $407.00 from $396.00 previously
Scotiabank upgraded Waters from Sector Perform to Sector Outperform and set a new price target of $450.00
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
Highlights Sales of $771 million exceeded guidance range; grew 9% as reported and 8% in constant currencyGAAP EPS of $2.47 and non-GAAP EPS of $2.95, above mid-point of guidance range Instruments grew mid-single-digits in constant currency, led by high-single-digit LC and MS growth – with continued strength in instrument replacement, particularly among large pharma and CDMO customersRecurring revenue grew 11% in constant currency, with 9% service growth and double-digit chemistry growthIn constant currency, Pharma grew 11% and Industrial grew 6%, while Academic & Government declined 3%, performing better than expectedRaising full-year 2025 constant currency sales growth guidance to +5.5% to
Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model Doubles Waters' total addressable market to approximately $40 billion, with 5-7% annual growthCreates a combined company with pro forma expected 2025 sales of approximately $6.5 billion and adjusted EBITDA of approximately $2.0 billion Increases annual recurring revenue to over 70% with over 80% of revenue coming from iconic market-leading brandsAnticipate approximately $345 million in annualized EBITDA synergies by 2030, including $200 million of cost synergies by year three, and $290 million of revenue synergies by year five Delivers a
MILFORD, Mass., July 11, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q2 2025 financial results conference call on Monday, August 4th, 2025 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least September 2nd, 2025, at midnight Eastern Time. About Waters Corporation Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of
Highlights Sales of $771 million exceeded guidance range; grew 9% as reported and 8% in constant currencyGAAP EPS of $2.47 and non-GAAP EPS of $2.95, above mid-point of guidance range Instruments grew mid-single-digits in constant currency, led by high-single-digit LC and MS growth – with continued strength in instrument replacement, particularly among large pharma and CDMO customersRecurring revenue grew 11% in constant currency, with 9% service growth and double-digit chemistry growthIn constant currency, Pharma grew 11% and Industrial grew 6%, while Academic & Government declined 3%, performing better than expectedRaising full-year 2025 constant currency sales growth guidance to +5.5% to
Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model Doubles Waters' total addressable market to approximately $40 billion, with 5-7% annual growthCreates a combined company with pro forma expected 2025 sales of approximately $6.5 billion and adjusted EBITDA of approximately $2.0 billion Increases annual recurring revenue to over 70% with over 80% of revenue coming from iconic market-leading brandsAnticipate approximately $345 million in annualized EBITDA synergies by 2030, including $200 million of cost synergies by year three, and $290 million of revenue synergies by year five Delivers a
MILFORD, Mass., July 11, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q2 2025 financial results conference call on Monday, August 4th, 2025 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least September 2nd, 2025, at midnight Eastern Time. About Waters Corporation Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
MILFORD, Mass., May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. The Aura™ platform from Halo Labs features a highly differentiated technology that performs full spectrum particle analysis and is complementary to the Waters light scattering detection solutions from its Wyatt Technology™ Portfolio. For example, its subvisible particle technology unlocks additional insights when characterizing external particles used to amplify CAR T-cells for cell therapy,
MILFORD, Mass., Aug. 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International. Heather is an accomplished leader who brings decades of experience across the pharma and medical device industries."Heather is an accomplished leader who brings decades of experience across the pharmaceutical and medical device industries, with a proven track record for
Waters™ Corporation (NYSE:WAT) today announced the appointment of Richard Fearon to its Board of Directors, effective March 27, 2023. Mr. Fearon is the former Vice Chairman and Chief Financial and Planning Officer of Eaton Corporation, a multinational power management company. "Rick's expertise is at the intersection of financial excellence, strategic development and transformation, which are the key pillars of Waters' growth plan. We are confident that Rick's unique skillset will complement our Board well and we look forward to benefiting from his insights as we continue to drive value for shareholders," said Dr. Flemming Ornskov, Chairman of the Board. Dr. Udit Batra, CEO and President,